Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Increases By 17.2%

Humacyte, Inc. (NASDAQ:HUMA) saw a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 4,910,000 shares, a growth of 17.2% from the May 15th total of 4,190,000 shares. Based on an average daily trading volume, of 2,020,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 5.4% of the shares of the company are short sold.

Humacyte Price Performance

Humacyte stock opened at $6.19 on Tuesday. The company has a market cap of $737.11 million, a price-to-earnings ratio of -6.19 and a beta of 1.61. The firm’s fifty day moving average is $5.52 and its 200 day moving average is $4.03. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.61. Humacyte has a 52-week low of $1.96 and a 52-week high of $9.97.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Sell-side analysts forecast that Humacyte will post -0.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on HUMA. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Humacyte in a report on Monday, April 1st. Piper Sandler reissued a “neutral” rating and issued a $4.00 target price on shares of Humacyte in a report on Tuesday, March 26th. Finally, Benchmark reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Friday, May 24th.

Insider Activity at Humacyte

In other Humacyte news, Director Gordon M. Binder bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was bought at an average cost of $6.78 per share, for a total transaction of $339,000.00. Following the completion of the transaction, the director now owns 160,000 shares of the company’s stock, valued at approximately $1,084,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Gordon M. Binder purchased 50,000 shares of the stock in a transaction on Wednesday, May 15th. The shares were acquired at an average price of $6.78 per share, with a total value of $339,000.00. Following the completion of the acquisition, the director now directly owns 160,000 shares of the company’s stock, valued at $1,084,800. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Heather Ledbetter Prichard sold 188,886 shares of Humacyte stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $8.14, for a total transaction of $1,537,532.04. Following the transaction, the chief operating officer now directly owns 2,625 shares in the company, valued at approximately $21,367.50. The disclosure for this sale can be found here. Over the last ninety days, insiders acquired 54,412 shares of company stock worth $369,107 and sold 1,628,820 shares worth $12,464,121. 23.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

Hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its stake in Humacyte by 261.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock valued at $26,000 after purchasing an additional 6,504 shares in the last quarter. Whittier Trust Co. of Nevada Inc. purchased a new stake in Humacyte during the fourth quarter valued at $28,000. Victory Capital Management Inc. bought a new position in Humacyte during the fourth quarter valued at $29,000. China Universal Asset Management Co. Ltd. increased its position in Humacyte by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $34,000 after acquiring an additional 9,325 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC bought a new position in Humacyte during the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.